CLIENT FOCUS

SOUTHEASTERN PATHOLOGY

March 2014 Issue # 2014-1

# SEP NOW OFFERING APTIMA TRICHOMONAS VAGINALIS ASSAY

The APTIMA Trichomonas vaginalis Assay, is an FDA-approved amplified nucleic acid test that detects Trichomonas vaginalis, the most common curable sexually transmitted infection in the U.S.

The assay may be used to test endocervical or vaginal swabs collected in APTIMA transport tubes, urine and specimens collected in a ThinPrep vial from symptomatic or asymptomatic women.

The APTIMA Trichomonas vaginalis Assay has a sensitivity of 100% and specificity of 99.6%.

The superior performance of this method compared to wet-mount microscopic examination and culture improves the screening, diagnosis, and treatment of trichomonas vaginalis infection.

It is estimated by the U.S. Centers for Disease Control that Trichomonas causes 7.4 million infections in the U.S. annually.

The World Health Organization estimates that there are 180 million new cases of Trichomonas infections annually worldwide, making it even more prevalent than Chlamydia and gonorrhea, the most common bacterial sexually transmitted infections.

Trichomonas vaginalis has been linked to several serious health outcomes including female infertility, pelvic inflammatory disease, premature births, and increased risk of HIV transmission.

If you have any questions, contact Jocelyn Mills #678-350-5050 or jmills@sepath.com.

**COLLECTION METHODS:**

- **ThinPrep Pap vial**
- **APTIMA Swab (endocervical/vaginal)**
- **APTIMA urine tube (women only)**

References

Centers for Disease Control and Prevention: Sexually Transmitted Diseases Treatment Guidelines